Shots:

• Gilteritinib is a FMS-like tyrosine kinase 3 (FLT3) and has inhibitory activity against FLT3-ITD which is a type of FLT3mut+ found in AML patients. Additionally- FLT3-ITD is a driver mutation that demonstrates high burden and poor prognosis
• The candidate is approved in the US and Japan in 2018- EU and Canada in 2019- in Korea- Brazil and Australia thus far in 2020 to treat adults with R/R FLT3mut+ AML. Till now it is available in the US- certain countries of EU and Japan
• In 2018- Astellas and Kotobuki Pharmaceutical collaborated to develop- manufacture and commercialize gilteritinib

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Astellas